Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ GPX8 Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA557787
Description
Immunogen sequence: WKYLVNPEGQ VVKFWRPEEP IEVIRPDIAA LVRQVII Highest antigen sequence identity to the following orthologs: Mouse - 70%, Rat - 70%.
GPX8 (Probable glutathione peroxidase 8) is also named as GSHPx-8 and belongs to the glutathione peroxidase family. Glutathione peroxidase (GPx) reduces hydroperoxides, including hydrogen peroxides, in the presence of reduced glutathione as a means of protecting organisms from oxidative damage. Several GPx isozymes have been identified in animal cells and these have been classified into different groups according to their cellular location and substrate specificity. In humans, eight types of GPx have been identified from GPx1 to GPx8. The full length GPX8 has 209 amino acids and the molecular weight is 24 kDa.
Specifications
| GPX8 | |
| Polyclonal | |
| Unconjugated | |
| GPX8 | |
| 2310016C16Rik; AU017063; EPLA847; glutathione peroxidase 8; glutathione peroxidase 8 (putative); GPX8; GPx-8; GSHPx-8; probable glutathione peroxidase 8; RGD1307506; UNQ847; UNQ847/PRO1785 | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 493869 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 0.3 mg/mL | |
| PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
| Q8TED1 | |
| GPX8 | |
| Recombinant protein corresponding to Human GPX8. Recombinant protein control fragment (Product #RP-104143). | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction